Bass keeps fishing for patent challenges

Continuing a string of patent challenges, hedge fund manager Kyle Bass filed an inter partes review (IPR) challenging a patent held by Celgene Corp. (NASDAQ:CELG) covering Revlimid lenalidomide. Celgene markets the thalidomide analog to treat mantle cell lymphoma (MCL), multiple myeloma (MM) and myelodysplastic syndromes (MDS).

The Coalition for Affordable Drugs VI filed the IPR on Wednesday with the U.S. Patent and Trademark Office challenging U.S. Patent No. 6,045,501, which issued in 2000 and covers methods for preventing fetal exposure to tetragenic drugs. The IPR argues Celgene's claims are obvious, noting initial rejections by the U.S. Patent Office on those grounds. ...